keyword
MENU ▼
Read by QxMD icon Read
search

Anidulafungin

keyword
https://www.readbyqxmd.com/read/28741344/anidulafungin-in-children-experience-in-a-tertiary-care-children-s-hospital-in-argentina
#1
María T Rosanova, Claudia Sarkis, Florencia Escarra, Carolina Epelbaum, Norma Sberna, Susana Carnovale, Carlos Figueroa, Rosa Bologna, Roberto Lede
The experience using anidulafungin for the treatment of invasive fungal infections in pediatrics is limited. In this article, we describe our experience in 55 children. Anidulafungin was administered intravenously at a loading dose of 3 mg/kg once daily, followed by 1.5 mg/kg every 24 hours over a mean period of 14 days (range: 7-22 days). Patients' median age was 114 months old (interquartile range: 32-168 months old). All patients had underlying diseases. Among patients with bone marrow transplant, the difference in white blood cell count, transaminase levels, and renal function at baseline and at the end of anidulafungin administration was not significant...
August 1, 2017: Archivos Argentinos de Pediatría
https://www.readbyqxmd.com/read/28702763/pharmacokinetics-of-antifungal-drugs-practical-implications-for-optimized-treatment-of-patients
#2
REVIEW
Romuald Bellmann, Piotr Smuszkiewicz
INTRODUCTION: Because of the high mortality of invasive fungal infections (IFIs), appropriate exposure to antifungals appears to be crucial for therapeutic efficacy and safety. MATERIALS AND METHODS: This review summarises published pharmacokinetic data on systemically administered antifungals focusing on co-morbidities, target-site penetration, and combination antifungal therapy. CONCLUSIONS AND DISCUSSION: Amphotericin B is eliminated unchanged via urine and faeces...
July 12, 2017: Infection
https://www.readbyqxmd.com/read/28699297/cost-effectiveness-analysis-of-anidulafungin-vs-fluconazole-for-the-treatment-of-invasive-candidiasis-ic-in-turkey
#3
Chin Fen Neoh, Esin Senol, Ates Kara, Ener Cagri Dinleyici, Stuart J Turner, David C M Kong
Anidulafungin has been shown to be non-inferior to, and possibly more efficacious, than fluconazole in treating patients with invasive candidiasis (IC). This study aimed to determine the cost-effectiveness of anidulafungin vs fluconazole for treatment of IC in the Turkish setting. A decision analytic model was constructed to depict downstream economic consequences of using anidulafungin or fluconazole for treatment of IC in the Turkish hospitals. Transition probabilities (ie treatment success, observed or indeterminate treatment failures) were obtained from a published randomised clinical trial...
July 12, 2017: Mycoses
https://www.readbyqxmd.com/read/28693479/pharmacoeconomic-analysis-of-antifungal-therapy-for-primary-treatment-of-invasive-candidiasis-caused-by-candida-albicans-and-non-albicans-candida-species
#4
Huang-Tz Ou, Tsung-Ying Lee, Yee-Chun Chen, Claudie Charbonneau
BACKGROUND: Cost-effectiveness studies of echinocandins for the treatment of invasive candidiasis, including candidemia, are rare in Asia. No study has determined whether echinocandins are cost-effective for both Candida albicans and non-albicans Candida species. There have been no economic evaluations that compare non-echinocandins with the three available echinocandins. This study was aimed to assess the cost-effectiveness of individual echinocandins, namely caspofungin, micafungin, and anidulafungin, versus non-echinocandins for C...
July 10, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28660773/successful-treatment-of-azole-resistant-candida-esophagitis-in-an-immunocompromised-pregnant-woman-using-anidulafungin
#5
Conner O Blackwell, Anandi N Sheth, Minh L Nguyen, Martina L Badell
No abstract text is available yet for this article.
June 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28605488/in-vitro-activity-of-the-novel-antifungal-compound-f901318-against-difficult-to-treat-aspergillus-isolates
#6
J B Buil, A J M M Rijs, J F Meis, M Birch, D Law, W J G Melchers, P E Verweij
Background: F901318 is a new antifungal agent with a novel mechanism of action with activity against Aspergillus species. We investigated the in vitro activity of F901318 against a collection of Aspergillus isolates. Methods: A total of 213 Aspergillus isolates were used in this study. A total of 143 Aspergillus fumigatus sensu stricto isolates were used, of which 133 were azole resistant [25 TR 34 /L98H; 25 TR 46 /Y121F/T289A; 33 A. fumigatus with cyp51A -associated point mutations (25 G54, 1 G432 and 7 M220); and 50 azole-resistant A...
June 10, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28601403/-activity-of-amphotericin-b-and-anidulafungin-alone-and-combined-against-candida-tropicalis-biofilms-developed-on-teflon-%C3%A2-and-titanium
#7
Marcelo Ernesto Fernández-Rivero, José L Del Pozo, Amparo Valentín, Victoria Fornes, Araceli Molina de Diego, Javier Pemán, Emilia Cantón
BACKGROUND: Current therapeutic strategies have a limited efficacy against Candida biofilms that form on the surfaces of biomedical devices. Few studies have evaluated the activity of antifungal agents against Candida tropicalis biofilms. OBJECTIVES: To evaluate the activity of amphotericin B (AMB) and anidulafungin (AND), alone and in combination, against C. tropicalis biofilms developed on polytetrafluoroethylene (teflon -PTFE) and titanium surfaces using time-kill assays...
June 14, 2017: Revista Iberoamericana de Micología
https://www.readbyqxmd.com/read/28597967/anidulafungin-for-the-treatment-of-candidaemia-caused-by-candida-parapsilosis-analysis-of-pooled-data-from-six-prospective-clinical-studies
#8
Dimitrios P Kontoyiannis, Matteo Bassetti, Marcio Nucci, Maria Rita Capparella, Jean L Yan, Jalal Aram, Patricia A Hogan
Concerns with echinocandin use for infections caused by Candida parapsilosis complex species have driven the need for data to support echinocandin clinical efficacy in such patients. Data from six prospective studies were pooled to assess efficacy and safety of anidulafungin in patients with candidaemia caused by C. parapsilosis. Patient-level data were pooled from patients with microbiologically confirmed candidaemia due to C. parapsilosis treated with anidulafungin. Patients received a 200 mg intravenous (IV) loading dose of anidulafungin (day 1) and 100 mg daily thereafter...
June 9, 2017: Mycoses
https://www.readbyqxmd.com/read/28584756/disseminated-cutaneous-trichosporonosis-in-an-adult-bone-marrow-transplant-patient
#9
A M Y Yong, S S Yang, K B Tan, S A Ho
The Trichosporon species are yeast-like opportunistic pathogens in immunocompromised patients. Trichosporon asahii infections have been reported in pediatric bone marrow transplant (BMT) patients. However, its incidence is low in the adult literature. A 52-year-old Chinese woman who was diagnosed with acute myeloid leukemia received induction chemotherapy and underwent allogenic bone marrow transplant, which was complicated by a relapse and required salvage chemotherapy. She developed persistent non-neutropenic fever secondary to presumed hepatosplenic candidiasis...
May 2017: Indian Dermatology Online Journal
https://www.readbyqxmd.com/read/28559257/susceptibility-testing-of-the-echinocandins-against-candida-species-in-the-daily-routine-etest%C3%A2-versus-sensititre-yeastone%C3%A2-data-from-a-single-center-in-austria
#10
Maria Aigner, Thomas Erbeznik, Martin Gschwentner, Cornelia Lass-Flörl
Antifungal susceptibility testing of caspofungin, anidulafungin and micafungin against Candida species was performed to evaluate the role of ETest® and Sensititre YeastOne® for antifungal susceptibility testing for daily routine and to survey resistance. 104 Candida species isolates detected from blood cultures were investigated. Determining EUCAST broth microdilution as reference method essential agreement (EA), categorical agreement (CA), very major errors (VME), major (ME) and minor errors (MIN) were assessed reading MICs at 18, 24 and 48 hours...
May 30, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28493006/activity-of-combined-antifungal-agents-against-multidrug-resistant-candida-glabrata-strains
#11
Laura Bedin Denardi, Jéssica Tairine Keller, Vanessa Oliveira, Débora Alves Nunes Mario, Janio Morais Santurio, Sydney Hartz Alves
In this study, we evaluated the in vitro activity of echinocandins, azoles, and amphotericin B alone and in combination against echinocandin/azole-sensitive and echinocandin/azole-resistant Candida glabrata isolates. Susceptibility tests were performed using the broth microdilution method in accordance with the Clinical and Laboratory Standards Institute document M27-A3. The checkerboard method was used to evaluate the fractional inhibitory concentration index of the interactions. Cross-resistance was observed among echinocandins; 15% of the isolates resistant to caspofungin were also resistant to anidulafungin and micafungin...
May 10, 2017: Mycopathologia
https://www.readbyqxmd.com/read/28480239/safety-and-efficacy-of-anidulafungin-for-fungal-infection-in-patients-with-liver-dysfunction-or-multiorgan-failure
#12
Anita Verma, Georg Auzinger, Michal Kantecki, James Campling, Dean Spurden, Fran Percival, Nigel Heaton
BACKGROUND: The objective of this study was to review our clinical experience on the safety and efficacy of anidulafungin, an echinocandin antifungal, in the treatment of invasive fungal infections (IFIs) in patients with moderate to severe abnormal liver function tests or multiorgan failure and IFI, in a large United Kingdom Liver Centre. METHODS: The clinical records of the first 50 consecutive patients treated for IFI with anidulafungin between January 7, 2009 and March 2, 2011 were analyzed...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28478968/an-unusual-case-of-urinary-tract-infection-caused-by-saprochaete-capitata-under-anidulafungin-treatment
#13
G Hazirolan, A Aypak, N Aksu
Saprochaete capitata may cause uncommon severe infections, especially in immunocompromised patients. Here, we describe a rare case of urinary tract infection by S. capitata in a chronic kidney disease and diabetes mellitus patient, which occur during anidulafungin therapy. Mycological examinations of urine were positive to S. capitata identified by mass spectrometry and confirmed by ITS sequencing. Minimum inhibitory concentration (MIC) of the isolate for amphotericin B, fluconazole, itraconazole, voriconazole and, anidulafungin were 2, 16, 1, 1, and 8μg/mL, respectively...
May 3, 2017: Journal de Mycologie Médicale
https://www.readbyqxmd.com/read/28473992/hepatotoxicity-of-antimycotics-used-for-invasive-fungal-infections-in-vitro-results
#14
Sandra Doß, Heike Potschka, Fanny Doß, Steffen Mitzner, Martin Sauer
Purpose. Drug-induced liver injury (DILI) is the most common cause of liver injury and a serious clinical problem; antimycotics are involved in approximately 3% of all DILI cases. The hepatotoxicity of many drugs, including the antimycotics, is poorly screened in human models. Methods. In a standardized assay the cytotoxicity on hepatocytes of different concentrations (Cmax, 5x Cmax, and 10x Cmax) of the antimycotics used for systemic infections was tested. Anidulafungin (ANI), liposomal amphotericerin B (L-AmB), caspofungin (CASPO), fluconazole (FLUCO), and voriconazole (VORI) were incubated with HepG2/C3A cells...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28459966/efficacy-of-anidulafungin-in-539-patients-with-invasive-candidiasis-a-patient-level-pooled-analysis-of-six-clinical-trials
#15
Bart Jan Kullberg, José Vasquez, Piroon Mootsikapun, Marcio Nucci, José-Artur Paiva, Jorge Garbino, Jean Li Yan, Jalal Aram, Maria Rita Capparella, Umberto Conte, Haran Schlamm, Robert Swanson, Raoul Herbrecht
Objectives: To evaluate the efficacy of anidulafungin for the treatment of candidaemia and invasive candidiasis in a large dataset, including patients with deep-seated tissue candidiasis, neutropenia and infection due to non- albicans Candida species. Methods: Data were pooled from six prospective, multicentre, multinational studies: four open-label, non-comparative studies of anidulafungin and two double-blind, double-dummy, randomized studies of anidulafungin versus caspofungin (clinical trial registrations: NCT00496197, NCT00548262, NCT00537329, NCT00689338, NCT00806351 and NCT00805740; ClinicalTrials...
April 28, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28456868/comparative-pathogenicity-of-lomentospora-prolificans-scedosporium-prolificans-isolates-from-mexican-patients
#16
Mariana Elizondo-Zertuche, Alexandra M Montoya, Efrén Robledo-Leal, Idalia Garza-Veloz, Ana L Sánchez-Núñez, Raquel Ballesteros-Elizondo, Gloria M González
We identified 11 Lomentospora prolificans isolates recovered from Mexican patients using phenotypic and molecular characteristics. The identification of isolates was assessed by internal transcribed spacer (ITS rDNA) sequencing. In vitro susceptibility to amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin and micafungin was determined according to Clinical and Laboratory Standards Institute (CLSI) procedures. Three isolates (07-2239, 11-2242 and 04-2673) were used to induce systemic infection in immunocompetent ICR mice...
August 2017: Mycopathologia
https://www.readbyqxmd.com/read/28448888/isolation-identification-and-characterization-of-potential-impurities-of-anidulafungin
#17
Lanning Zhao, Qilong Wang, Yi Bie, Xiaoxia Lu
Eight impurities ranging from 0.03 to 0.97% in anidulafungin bulk drug were detected by HPLC. Four impurities (Imp-I, Imp-II, Imp-III and Imp-VIII) among impurities were isolated from the self-prepared or marketed samples of anidulafungin bulk drug by means of preparative HPLC. A thorough study was undertaken to characterize these impurities and based on 1D ((1)H, (13)C, H-D, DEPT 90 and 135) and 2D (COSY, TOCSY, HSQC, HMBC) NMR and ESI-MS spectral data. Based on the characterization data, Imp-I was found to be known open-chain hydrolysis product formed during the synthesis and degradation...
April 17, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28438935/candida-guilliermondii-complex-is-characterized-by-high-antifungal-resistance-but-low-mortality-in-22-cases-of-candidemia
#18
Laura Judith Marcos-Zambrano, Mireia Puig-Asensio, Felipe Pérez-García, Pilar Escribano, Carlos Sánchez-Carrillo, Oscar Zaragoza, Belén Padilla, Manuel Cuenca-Estrella, Benito Almirante, M Teresa Martín-Gómez, Patricia Muñoz, Emilio Bouza, Jesús Guinea
The objectives of our study were to describe the characteristics of patients with Candida guilliermondii candidemia and to perform an in-depth microbiological characterization of isolates and compare them with those of patients with C. albicans candidemia. We described the risk factors and outcomes of 22 patients with candidemia caused by the C. guilliermondii complex. Incident isolates were identified using molecular techniques, and susceptibility to fluconazole, anidulafungin, and micafungin was studied. Biofilm formation was measured using the crystal violet assay (biomass production) and the XTT reduction assay (metabolic activity), and virulence was studied using the Galleria mellonella model...
July 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28437176/echinocandins-in-ocular-therapeutics
#19
Akash Patil, Soumyajit Majumdar
Fungal infections of the eye, especially fungal keratitis and endophthalmitis, are major causes of concern and if left untreated could lead to vision loss. Currently, natamycin (polyene antifungal) is the only commercially available topical agent used for the treatment of ocular fungal infections. The other antifungals, belonging to the polyene and azole classes, are used off-label in treating ocular infections and are administered topically, orally, intraocularly, or systemically. Even though their use through the different routes of administration has shown favorable outcomes, challenges such as poor ocular penetration, low bioavailability, ocular toxicity, and systemic side effects limit their utility...
June 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28419092/a-multi-centric-study-of-candida-bloodstream-infection-in-lima-callao-peru-species-distribution-antifungal-resistance-and-clinical-outcomes
#20
MULTICENTER STUDY
Lourdes Rodriguez, Beatriz Bustamante, Luz Huaroto, Cecilia Agurto, Ricardo Illescas, Rafael Ramirez, Alberto Diaz, Jose Hidalgo
BACKGROUND: The incidence of candidemia is increasing in developing countries. Very little is known about the epidemiology of candidemia in Peru. The aim of this study is to describe the incidence, microbiology, clinical presentation and outcomes of Candida bloodstream infections in three Lima-Callao hospitals. METHODS: Candida spp. isolates were identified prospectively at participant hospitals between November 2013 and January 2015. Susceptibility testing for amphotericin B, fluconazole, posaconazole, voriconazole and anidulafungin was performed using broth microdilution method...
2017: PloS One
keyword
keyword
54240
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"